On May 21, 2026 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, reported the successful pricing of a private placement financing round. This transaction is expected to raise an aggregate of approximately $5.5 million in gross proceeds. With these funds the Company will focus on advancing its lead ADC program utilizing its unique RNA splicing modulator payload, AKTX-101, toward a first-in-human Phase 1 clinical trial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This financing reflects deep conviction from our long-term strategic investors and positions Akari to build on our strong momentum to accelerate our lead ADC program towards clinical data, pursue strategic partnerships, and unlock the full potential of our novel ADC platform," stated, Abizer Gaslightwala, Akari’s CEO.

The Company entered into definitive purchase agreements with the investors for the issuance and sale of 1,470,588 unregistered American Depository Shares (ADSs), or prefunded warrants in lieu thereof, and unregistered Series H Warrants, Series I Warrants and Series J Warrants ("the Offering"). The ADSs were priced at $3.74 per ADS.

The gross cash proceeds from the Offering are expected to be approximately $5.5 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes.

The issuance of the Series H, I and J Warrants is subject to the Company obtaining shareholder approval and will each be exercisable for 1,470,588 ADSs. The Series H Warrants will have an exercise price of $3.74 per ADS, have a term of 18 months, and will be immediately exercisable. The Series I Warrants will have an exercise price of $3.74 per ADS, have a term of 60 months, and will be immediately exercisable. The Series J Warrants will have an exercise price of $3.74 per ADS, have a term of 60 months, and will be immediately exercisable.

Paulson Investment Company LLC is acting as placement agent for the financing. The gross proceeds of the private placement will be funded in three separate tranches pursuant to three separate closings, expected to occur between May 27, 2026 and July 15, 2026.

The ADSs and warrants described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act") and Regulation D promulgated thereunder and have not been registered under the Act or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from such registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Akari Therapeutics, MAY 21, 2026, View Source [SID1234665914])